| Literature DB >> 35372757 |
Marieke Nederend1,2, Katja Zeppenfeld1, Monique R M Jongbloed1,2,3, Anastasia D Egorova1,2.
Abstract
Background: Patients with a systemic right ventricle (sRV) in the context of transposition of the great arteries (TGA) late after atrial switch are prone to heart failure. Complications like tricuspid valve regurgitation (TR) can further aggravate sRV dysfunction. Tricuspid valve regurgitation is usually secondary to annular dilatation and restriction. Criteria for cardiac resynchronization therapy (CRT) in this patient group are not well defined and should be considered on a case-by-case basis. Case summary: We present a case of a 42-year-old male with sRV failure and TR in the context of TGA after atrial switch. Patient had progressive reduction in exercise capacity. Electrocardiogram showed a wide QRS complex (right bundle branch block configuration). Echocardiography showed significant TR and signs of electromechanical dyssynchrony of the failing sRV with severely reduced systolic function. He underwent heart catheterization and invasive haemodynamic evaluation to assess the potential benefit of CRT. During sequential atrial-sRV pacing, 20% increase in Dp/Dt was measured, suggesting that he would be a CRT responder. Concomitant angiography showed no baffle leakage nor obstructive coronary artery disease. Hybrid CRT-defibrillator implantation resulted in successful resynchronization and improved sRV function, reduced TR and better exercise capacity. Discussion: Invasive haemodynamic contractility evaluation can help assess the potential benefit of CRT in patients with systemic right ventricular failure in the context of transposition of TGA after atrial switch. Successful CRT can result in improved sRV function, reduced TR and improved exercise capacity.Entities:
Keywords: Cardiac resynchronization therapy; Congenital heart disease; Device therapy; Heart failure; Systemic right ventricle; Transposition of the great arteries
Year: 2022 PMID: 35372757 PMCID: PMC8972821 DOI: 10.1093/ehjcr/ytac087
Source DB: PubMed Journal: Eur Heart J Case Rep ISSN: 2514-2119
Figure 1(A) Postero-anterior and (B) lateral chest X-ray image of the patient illustrating the cardiomegaly. (C) A 12-lead electrocardiogram with a broad QRS (180 ms) complex in a right bundle branch block configuration. Red: systemic right ventricle; blue: subpulmonic left ventricle; yellow: Amplatzer occluder device.
Figure 2Transverse plane of the cardiac magnetic resonance imaging illustrating the anatomy and coronary sinus draining into the pulmonary venous return atrium (systemic circulation). Red: systemic right ventricle; blue: subpulmonic left ventricle; orange: coronary sinus; green: pulmonary venous return atrium.
Figure 3The intraventricular pressure curves registered during the invasive haemodynamic evaluation of the different pacing modalities. (A) During atrial pacing 90/min with intrinsic atrioventricular conduction and (B) during sequential pacing 90/min (atrial-systemic right ventricle pacing) with an atrioventricular delay of 260 ms.
Figure 4(A) Postero-anterior and (B) lateral chest X-ray image of the patient with the hybrid cardiac resynchronization therapy-defibrillator in situ. (C) A 12-lead electrocardiogram during biventricular pacing showing significant QRS narrowing. Red: systemic right ventricle; blue: subpulmonic left ventricle; yellow: Amplatzer occluder device. Black arrow: epicardial leads on systemic right ventricle; blue arrow: atrial lead in the systemic venous return atrium; orange arrow: implantable cardioverter-defibrillator shock lead in the subpulmonic left ventricle.
| 1974 | Congenital defects/anatomy: dextro-transposition of the great arteries. |
| 1974 | Atrial switch operation according to Mustard; |
| 1976 | Pulse generator pocket infection with |
| 2010 | Cerebral abscess and baffle leak: surgical baffle revision; |
| 2017 | Symptomatic sRV failure: New York Heart Association (NYHA) II and reduced exercise capacity [140 Watt (73% of predicted), VO2max of 16.1 mL/min/kg (46% of predicted)]; |
| 2018 | Subjective improvement to NYHA I–II and improved maximal exercise capacity [156 Watt (83% of predicted), VO2max of 19.1 mL/min/kg (55% of predicted)]; |